Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis

Cited by (407)

Items 101–200 of 407

1. Depression, Estrogens, and Neuroinflammation: A Preclinical Review of Ketamine Treatment for Mood Disorders in Women
   Collin Gagne, Alexandre Piot, Wayne G. Brake · 2022 · Frontiers in Psychiatry
2. A Retrospective Naturalistic Study Comparing the Efficacy of Ketamine and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression
   Georgios Mikellides, Panayiota Michael, Lilia Psalta, Teresa Schuhmann, Alexander Thomas Sack · 2022 · Frontiers in Psychiatry
3. Ketamine: Recent evidence and current uses
   Ehab El Shahat Afify, Samar Mohamed, M. Bahaa Khedr · 2023 · Benha Journal of Applied Sciences
4. Anesthesia and the neurobiology of fear and posttraumatic stress disorder
   Keith M. Vogt, Kane O. Pryor · 2022 · Current Opinion in Anaesthesiology
5. Efficacy and safety of esketamine for perioperative depression in patients undergoing elective surgery: A meta-analysis of randomized controlled trials
   Xue-jie Lou, Di Qiu, Zhuo-Yu Ren, Kenji Hashimoto, Guang-Fen Zhang, Jianjun Yang · 2024 · Asian Journal of Psychiatry
6. Evidence from preclinical and clinical metabolomics studies on the antidepressant effects of ketamine and esketamine
   Daniele Cavaleri, Ilaria Riboldi, Cristina Crocamo, Giuseppe Paglia, Giuseppe Carrà, Francesco Bartoli · 2024 · Neuroscience Letters
7. Ketamine and Esketamine for Depression in Daily Practice
   Balwinder Singh · 2024 · Journal of Clinical Psychopharmacology
8. Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram
   Chao Dong, Z. Ryan Tian, Yūkō Fujita, Atsuhiro Fujita, Noriko Hino, Michihiko Iijima, Kenji Hashimoto · 2021 · Pharmacology Biochemistry and Behavior
9. Blinding and expectancy confounds in psychedelic randomised controlled trials
   Muthukumaraswamy, Suresh, Forsyth, Anna, Lumley, Thomas · 2021
10. Suicidal ideation following ketamine prescription in patients with recurrent major depressive disorder: a nation-wide cohort study
    Yiheng Pan, Maria P. Gorenflo, Pamela B. Davis, David C. Kaelber, Susan M. De Luca, Rong Xu · 2024 · Translational Psychiatry
11. The effect of ketamine on cognition, anxiety, and social functioning in adults with psychiatric disorders: A systematic review and meta-analysis
    Mattia Marchi, Federica Maria Magarini, Giacomo Galli, Federico Mordenti, Antonio Travascio, Daniele Uberti, Edoardo De Micheli, Luca Pingani, Sílvia Ferrari, Gian Maria Galeazzi · 2022 · Frontiers in Neuroscience
12. The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial
    Haiyan Liu, Xiaofeng Lan, Chengyu Wang, Fan Zhang, Ling Fu, Weicheng Li, Yanxiang Ye, Zhibo Hu, Ziyuan Chao, Yuping Ning et al. · 2022 · BMC Psychiatry
13. Effect of esketamine on postpartum depression after labor analgesia and potential mechanisms: a randomized, double-blinded controlled trial
    Wei Ting Wang, Bin Ling, Haibo Zhao, Jing He, Hua Xu, Jie Lv, Qi Wang · 2024 · BMC Anesthesiology
14. Ketamine in multiple treatment-resistant depressed inpatients: A naturalistic cohort study
    Stefan Vestring, Viktoria Galuba, Elisa Kern, Sabine Voita, Franziska Berens, Danial Nasiri, Katharina Domschke, Claus Normann · 2024 · Journal of Affective Disorders
15. The role and mechanism of esketamine in preventing and treating remifentanil-induced hyperalgesia based on the NMDA receptor–CaMKII pathway
    Jiafang Wang, Yankun Feng, Qi Zhong, Jin Li, Zhijun Chen, Jinming Zhang, Degang Zhu · 2024 · Open Life Sciences
16. Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents
    Octavian Vasiliu · 2022 · Frontiers in Pharmacology
17. Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention—Mechanisms and Pharmacodynamics
    Hui Song, Yang Luo, Lingzhi Fang · 2024 · Neuropsychiatric Disease and Treatment
18. Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
    Raquel Bennett, Christian Yavorsky, GARY L. BRAVO · 2022 · Frontiers in Psychiatry
19. Suicidal behavior-advances in clinical and neurobiological research and improvement of prevention strategies
    Thomas Sobanski, Gregor Peikert, Ulrich W. Kastner, Gerd Wagner · 2022 · World Journal of Psychiatry
20. The NMDA receptor antagonists memantine and ketamine as anti-migraine agents
    Karolina Podkowa, Kamil Czarnacki, Agnieszka Borończyk, Michał Borończyk, Justyna Paprocka · 2023 · Naunyn-Schmiedeberg s Archives of Pharmacology
21. Chirality in Modern Antidepressants: A Comprehensive Review of Stereochemical Impacts on Pharmacology and Therapeutics
    Gabriel Hancu, Alexandra Uilăcan, Nicoleta Mirela Blebea · 2024 · Drugs and Drug Candidates
22. Unravelling the neuroinflammatory links in depression: the potential of a lipopolysaccharide preclinical model
    Leandrie Pienaar, Sooraj Baijnath, Aletta M. E. Millen · 2024 · Discover Medicine
23. Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis
    Mattia Marchi, Riccardo Farina, Karim Rachedi, Francesca Laonigro, Marija Franka Žuljević, Luca Pingani, Sílvia Ferrari, Metten Somers, Marco P. Boks, Gian Maria Galeazzi · 2024 · Journal of Psychopharmacology
24. Preliminary evidence for preserved synaptic density in late-life depression
    Vande Casteele, Thomas, Laroy, Maarten, Van Cauwenberge, Margot, Koole, Michel, Dupont, Patrick, Sunaert, Stefan, Van den Stock, Jan, Bouckaert, Filip, Van Laere, Koen, Emsell, Louise et al. · 2024 · Translational Psychiatry
25. ERAS Protocol Options for Perioperative Pain Management of Substance Use Disorder in the Ambulatory Surgical Setting
    Nicholas Zwolinski, Kaiwal Patel, Nalini Vadivelu, Gopal Kodumudi, Alan D. Kaye · 2023 · Current Pain and Headache Reports
26. BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression
    Ezio Carboni, Anna Rosa Carta · 2022 · Journal of Integrative Neuroscience
27. Response to intravenous racemic ketamine after switch from intranasal (S)‐ketamine on symptoms of treatment‐resistant depression and post‐traumatic stress disorder in Veterans: A retrospective case series
    Sean Bentley, Hewa Artin, Eamonn Mehaffey, Fred Liu, Kevin Sojourner, Andrew W. Bismark, David Printz, Ellen Lee, Brian Martis, Sharon De Peralta et al. · 2022 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
28. Ketamine for suicidality: An umbrella review
    Ahmad Shamabadi, Ali Ahmadzade, Alireza Hasanzadeh · 2022 · British Journal of Clinical Pharmacology
29. Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study
    Melody J.Y. Kang, Gustavo Héctor Vázquez · 2022 · Journal of Affective Disorders
30. Update on the assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form-2 (ATHF-SF2)
    Harold A. Sackeïm, Scott T. Aaronson, Mark T. Bunker, Charles R. Conway, Mark S. George, Hamish McAllister-Williams, Joan Prudic, Michael E. Thase, Allan Hunter Young, A. John Rush · 2024 · Journal of Psychiatric Research
31. Effect of continuous esketamine infusion on brain white matter microstructure in patients with major depression: A diffusion tensor imaging study
    Xiang Liu, Zhipeng Wei, Lifeng Li, Jiangping Li, Yingke Deng, Yumeng Liu, Haijun Li, Dechang Peng, Xin Wan, Guangyao Wu · 2024 · Journal of Affective Disorders
32. Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders
    Caitlin S. Yee, Anees Bahji, María Lolich, Gustavo Héctor Vázquez, Ross J. Baldessarini · 2022 · Journal of Clinical Psychopharmacology
33. (Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy
    Alexandra A. Alario, Mark J. Niciu · 2022 · Chronic Stress
34. Comparative safety and tolerability of ketamine and esketamine for major depressive disorder: a systematic review and meta-analysis
    Haoning Guo, Liling Tang, Miaoquan He, Wencheng Tang, Jing Liu, Silin Wu, Shuying Yuan, Jisheng Wang, Xueli Tang · 2025 · Frontiers in Pharmacology
35. Listening to music during intranasal (es)ketamine therapy in patients with treatment-resistant depression correlates with better tolerability and reduced anxiety
    Johannes Hauser, Jan Sarlon, Timur Liwinski, Annette Beatrix Brühl, Undine Emmi Lang · 2024 · Frontiers in Psychiatry
36. Modulating factors in mood disorders treatment
    Alessandro Serretti · 2023 · International Clinical Psychopharmacology
37. Management of Depression and Anxiety in Perioperative Medicine
    Megan L. Rolfzen, Peter Nägele, Charles R. Conway, Robert David Gibbons, Karsten Bartels · 2024 · Anesthesiology
38. Ketamine in COVID‐19 patients: Thinking out of the box
    Karolina Akinosoglou, Αθανάσιος Γώγος, Charalabos Papageorgiou, Elias K. Angelopoulos, Charalambos A. Gogos · 2020 · Journal of Medical Virology
39. Designing Clinical Trials to Assess the Impact of Pharmacological Treatment for Suicidal Ideation/Behavior: Issues and Potential Solutions
    Zhixing Yao, William Vaughn McCall · 2023 · Pharmaceutical Medicine
40. Activation of σ1-Receptors by R-Ketamine May Enhance the Antidepressant Effect of S-Ketamine
    Hans O. Kalkman · 2023 · Biomedicines
41. Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023
    Li-yuan Zhao, Guang-Fen Zhang, Xue-jie Lou, Kenji Hashimoto, Jianjun Yang · 2024 · European Archives of Psychiatry and Clinical Neuroscience
42. “Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality
    Neethu K Nandan, Puneet Kumar Soni, Ajay K. Parsaik, Aqeel Hashmi · 2022 · Cureus
43. Esketamine–A quick-acting novel antidepressant without the disadvantages of ketamine
    Sheikh Shoib, Madhulika Kotra, Sana Javed, Vinh-Son Nguyen, Barikar Chandrappa Malathesh · 2022 · Hormone Molecular Biology and Clinical Investigation
44. The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis
    Idevaldo Floriano, Antônio Silvinato, Wanderley Marques Bernardo · 2023 · Revista da Associação Médica Brasileira
45. Cognitive changes in patients with unipolar TRD treated with IV ketamine: A systematic review
    Verónica Grasso, Gilmar Gutiérrez, Najat Alzbeidi, Carolina V. Hernandorena, Gustavo Héctor Vázquez · 2024 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
46. Ketamine in fibromyalgia: a systematic review
    Jozélio Freire de Carvalho, Eduardo Pondé de Sena · 2024 · Revista Brasileira de Reumatologia
47. Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders
    Aleksandra Wisłowska-Stanek, Michał Jarkiewicz, Dagmara Maria Mirowska-Guzel · 2024 · Pharmacological Reports
48. Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the use of ketamine in psychiatric practice
    Salam Hussain, Christopher K Gale, Shanthi Sarma, Jeremy P Smith, Adam J. Bayes, Colleen K A Loo · 2025 · Australian & New Zealand Journal of Psychiatry
49. Does route of administration affect antidepressant efficacy of ketamine? A meta-analysis of double-blind randomized controlled trials comparing intravenous and intranasal administration
    Marvin Sören Meiering, David Weigner, Matti Gärtner, Thomas Schäfer, Simone Grimm · 2022 · Journal of Psychiatric Research
50. The effect and mechanism of low-dose esketamine in neuropathic pain-related depression-like behavior in rats
    Lijuan Wang, Shuwu Zhao, Jiali Shao, Chen Su · 2024 · Brain Research
51. Esketamine Provides Neuroprotection After Intracerebral Hemorrhage in Mice via the NTF3 / PI3K / AKT Pathway
    Xiaoyu Niu, Yuanyuan Zheng, Wang Wang, Liwei Zhang, Shaoshuai Wang, Xihua Lu, Junyang Wang, Gaiqing Yang, Ting C. Zhao, Qiang Li et al. · 2024 · CNS Neuroscience & Therapeutics
52. Effects of the subanesthetic dose of esketamine on postoperative sleep quality in patients undergoing modified radical mastectomy: a randomized, double-blind controlled trial
    Ying Chen, Junchen He, Rong Huang, Zhuoqi Pan, Min Zhong, Wenxuan Zhang · 2025 · Frontiers in Medicine
53. Ketamine in Clinical Practice: Transitioning from Anesthetic Agent to Psychiatric Therapeutic
    Jose-Manuel Quintero, Rosa‐Helena Bustos, Sharon Lechtig, Stephania Beltran, Carlos A. Zarate · 2025 · Cambridge University Press eBooks
54. The effect of low-dose esketamine on maternal depression after cesarean delivery
    Y. Shang, Siyuan Li, Q. Zheng, Tingting Mi, Yu-Zhu Lv, Lichun Han, Bin-Rong Wang · 2025 · Journal of Psychosomatic Obstetrics and Gynaecology
55. Esketamine disinhibits brain networks in depression: Evidence from oscillatory and aperiodic activity
    Verina Guirguis, Sanvi Korsapathy, Francesca Pupillo, Robert K. McClure, David Zarzar, Mengsen Zhang, Flavio Frӧhlich, Tobias Schwippel · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
56. Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorder
    Sipan Haikazian, Roger S. McIntyre, Shakila Meshkat, Kevin Kratiuk, Cristian-Daniel Llach, Diana K. Orsini, Sara D Di Luch, Joshua Daniel Rosenblat · 2025 · Psychiatry Research
57. Cognitive and psychotic effects of ketamine “short- vs. long-term” therapy in a rat model of depression: Hippocampal TrkB/Akt/GSK-3β/mTOR/autophagy trajectories
    Salehi Aref, Mohamed Z. Habib, Dalia Eid, Eman Hamdy Badr Eltantawy, Mohamed Taeimah, Fatma E. Hassan, Dina Aly El‐Gabry, Heba Hamed ElShahawi, Magda I. Mohamad, Ahmed M. Abdel-Tawab et al. · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
58. Dysfunction of GluN3A subunit is involved in depression-like behaviors through synaptic deficits
    Mengmeng Zhang, Xiangru Kong, Jing Chen, Wenqin Liu, Can Liu, Xiaoyun Dou, Lin Hong Jiang, Yanmin Luo, Mingrui Song, Peng Miao et al. · 2023 · Journal of Affective Disorders
59. Ketamine for catatonia: A novel treatment for an old clinical challenge? A systematic review of the evidence
    Ana Teresa Caliman‐Fontes, Flávia Vieira, Gustavo Carneiro-Gomes Leal, Beatriz A. Carneiro, Yana Quarantini-Alvim, Taiane V Andrade, Rodrigo Paixão Mello, Ary Gadelha, Acioly L.T. Lacerda, Lucas C. Quarantini · 2024 · Schizophrenia Research
60. Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
    Maximilian Carter, Kassandra Solsrud, Nicholas Mischel · 2022 · Frontiers in Psychiatry
61. Pharmacological Mechanism of Ketamine in Suicidal Behavior Based on Animal Models of Aggressiveness and Impulsivity: A Narrative Review
    Thi Mai Loan Nguyen, Fabrice Jollant, Laurent Tritschler, Romain Colle, Emmanuelle Corruble, Alain Michel Gardier · 2023 · Pharmaceuticals
62. Ketamine in depression and electroconvulsive therapy
    Irene Rozet · 2021 · Current Opinion in Anaesthesiology
63. Ensuring the affordable becomes accessible–lessons from ketamine, a new treatment for severe depression
    Anthony Rodgers, Dilara Bahceci, Christopher G. Davey, Mary Lou Chatterton, Nick Glozier, Malcolm Hopwood, Colleen K A Loo · 2023 · Australian & New Zealand Journal of Psychiatry
64. Symptom modulation and tolerability of intravenous ketamine in treatment-resistant bipolar depression: A retrospective study
    Alessandro Cuomo, Simone Pardossi, Giovanni Barillà, Pietro Carmellini, Bernardo Firenzuoli, Francesca Tarantino, Rebecca Tinturini, Andrea M. Fagiolini · 2025 · Journal of Affective Disorders
65. Towards an expanded neurocognitive account of ketamine’s rapid antidepressant effects
    Yingliang Dai, Ben J. Harrison, Christopher G. Davey, Trevor Steward · 2025 · The International Journal of Neuropsychopharmacology
66. Impact of perioperative esketamine on the perioperative neurocognitive dysfunction: a systematic review and meta-analysis of randomised controlled studies
    Xuesen Su, Lu Chen, Yanan Zhao, Chao Li, Shufang Liu, Zixuan Wang, Jiayu Zhu, Xin Yuan, Yihe Tian, Shouyuan Tian · 2025 · BMJ Open
67. Ketamine and Esketamine in Psychiatry: A Comparative Review Emphasizing Neuroplasticity and Clinical Applications
    Georgios Mikellides · 2025 · Psychoactives
68. Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review
    Jess Kerr‐Gaffney, Anna Tröger, Alice Caulfield, Philipp S. Ritter, James Rucker, Allan Hunter Young · 2025 · Journal of Psychopharmacology
69. Developmental toxicity and transcriptome analysis of zebrafish (Danio rerio) embryos exposed to anesthetic esketamine
    Jiao Wang, Ying Zhang, Ying Liu, Zeling You, Jiaolong Huang, Kai Lian, Peng Duan, Qi Jiang · 2025 · Chemico-Biological Interactions
70. The role of frontal EEG in predicting clinical response of major depressive disorder to intranasal ketamine and esketamine
    Carlos Trenado, Erich Seifritz, Sebastian Olbrich, Stefano Ferrea · 2025 · Journal of Affective Disorders
71. Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)—Phase II single-arm open-label feasibility study
    Wei Lee, Caitlin Sheehan, Richard Chye, Sungwon Chang, Adam J. Bayes, Colleen K A Loo, Brian Draper, Meera Ruth Agar, David C. Currow · 2023 · PLoS ONE
72. The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review
    Carolina Sepulveda Ramos, Matthew Thornburg, Kelly Long, Kiran Sharma, Julia Roth, Diana Lacatusu, Reece Whitaker, Daniel Pacciulli, Sulma Moredo Loo, Mohammad Manzoor et al. · 2022 · Cureus
73. The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice
    Cindy A. Stein, Andrew Penn, Stephanie Hope, Caroline G. Dorsen, Mariavittoria Mangini · 2022 · Journal of Midwifery & Women s Health
74. Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care: A systematic review
    Matheus Ghossain Barbosa, Gabriela Takayanagi Garcia, Luciana Maria Sarin, Andrea Parolin Jackowski · 2022 · Brazilian Journal of Psychiatry
75. Differential effectiveness between Ketamine and Esketamine: the predictive role of dissociative features. A treatment-resistant depression case
    Nicola Ragone, Barbara Barbini, Carolina Passani, Federico Seghi, Cristina Colombo · 2023 · International Clinical Psychopharmacology
76. Clinical predictive factors and trajectories of suicidal remission over 6 weeks following intravenous ketamine for suicidal ideation
    Fabrice Jollant, Christophe Dematteï, Pascale Fabbro-Péray, Mocrane Abbar · 2023 · Journal of Affective Disorders
77. Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices
    Kaike Thiê da Costa Gonçalves, Vagner Deuel de Oliveira Tavares, Maria Luiza de Morais Barros, Aldielyson Jorge Cavalcante de Brito, Patrícia Cavalcanti-Ribeiro, Fernanda Palhano-Fontes, Marcelo Falchi-Carvalho, Emerson Arcoverde, RAFAEL GUIMARÃES DOS SANTOS, Jaime E. C. Hallak et al. · 2024 · European Archives of Psychiatry and Clinical Neuroscience
78. Spravato for Treatment-Resistant Depression: Efficacy and Sexual Side Effect Profile
    A. Raza, Ghazi Uddin Ahmed, Habiba Zafar, Syed Owais Akhtar, Muhammad Bin Mobin, Abedin Samadi · 2025 · Neuropsychiatric Disease and Treatment
79. Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine
    Rodolphe Lebeau, Indira Mendez‐David, Laura Kuczynski-Noyau, Céline Henry, David Attali, Marion Plaze, Romain Colle, Emmanuelle Corruble, Alain Michel Gardier, Raphaël Gaillard et al. · 2022 · Frontiers in Pharmacology
80. Progesterone alleviates esketamine-induced hypomyelination via PI3K/Akt signaling pathway in the developing rat brain
    Peiwen Liu, Kan Zhang, Chaoyang Tong, Ting Liu, Jijian Zheng · 2023 · Biotechnology and Genetic Engineering Reviews
81. Self-medication with Novel Psychoactive Substances (NPS): a Systematic Review
    Tayler Holborn, Robert Lee Page II, Fabrizio Schifano, Paolo Deluca · 2023 · International Journal of Mental Health and Addiction
82. Suicide prevention and ketamine: insights from computational modeling
    Charlton, Colleen E., Karvelis, Povilas, McIntyre, Roger S., Diaconescu, Andreea O. · 2023 · Frontiers in Psychiatry
83. National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder
    Mark J. Niciu, Robert C. Meisner, Brent R. Carr, Ali A. Farooqui, David Feifel, Adam Ian Kaplin, Ellen Kendrick, Paul M. Kim, Christopher D. Schneck, Jennifer L. Vande Voort et al. · 2023 · Journal of Affective Disorders
84. Comments to Drs. Bahji, Vazquez, and Zarate
    Wayne Curtis Drevets, Vanina Popova, Ella Daly, Stephane Borentain, Rosanne Lane, M. Soledad Cepeda, Maju Mathews, Husseini K. Manji, Carla M. Canuso · 2021 · Journal of Affective Disorders
85. Effect of ketamine and esketamine on RNA expression and its relevance for depression: A systematic review
    Claudia Pisanu, Rosana Carvalho Silva, Mattia Meattini, Massimo Gennarelli, Bernhard Theodor Baune, Alessio Squassina, Alessandra Minelli · 2025 · Pharmacological Research
86. Changes in dynamic and static functional connectivity in amygdala subregions in major depressive disorder treated with esketamine in and sertraline: A pilot study
    Xiang Liu, Lifeng Li, Haijun Li, Yingke Deng, Yumeng Liu, Dechang Peng, Guangyao Wu, Xueming Zhou · 2025 · Journal of Affective Disorders
87. Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology
    Yinxin Wang, Jiangang Xu, Xinyu Zhou, Lu Che, Minghan Qiu, Yang Liu, Ming Gao, Zhen Yang · 2025 · Advanced Science
88. A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?
    Gia Han Le, Sabrina Wong, Danica E. Johnson, Andy Lu, Diana K. Orsini, Noah Chisamore, Sara D Di Luch, Joshua Daniel Rosenblat, Roger S. McIntyre · 2025 · Journal of Affective Disorders
89. Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry
    Joseph J. Taylor, Balázs Szigeti, Noah D. Silverberg, Masoud Ahmadzad-Asl, Marina R. Kare, Ryan D. Webler, Diana K. Orsini, Joshua Daniel Rosenblat, Tom Bschor, Christopher Baethge et al. · 2026 · The Lancet Psychiatry
90. Behavioral sensitization and tolerance induced by repeated treatment with ketamine enantiomers in male Wistar rats
    Kristian Elersič, Anamarija Banjac, Marko Živin, Maja Zorović · 2024 · PLoS ONE
91. Depression, an unmet health need in Africa: Understanding the promise of ketamine
    Aletta M. E. Millen, Willie M. U. Daniels, Sooraj Baijnath · 2024 · Heliyon
92. Effect of Ketamine Treatment on Social Withdrawal in Autism and Autism-Like Conditions
    Megan Jayne Ralston, Alim Osman, Pavan Suryadevara, Elissa Cleland · 2024 · Clinical Neuropharmacology
93. Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a Working Group appointed by the National Consultant in the field of psychiatry
    Piotr Gałecki, Katarzyna Maria Bliźniewska-Kowalska, Wiesław Jerzy Cubała, Anna Depukat, Anna Mosiołek, JANUSZ K. RYBAKOWSKI, Jerzy Samochowiec, Bogusław Sobolewski, Agata Szulc, Dominika Dudek · 2024 · Psychiatria Polska
94. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration
    Michael D. Banov, Rachel E. Landrum, Michelle B. Moore, Steven T. Szabo · 2021 · Journal of Clinical Psychopharmacology
95. Mechanism of action of antidepressants
    Kuldeepak Sharma, Ankush Sundriyal, Aanchal Loshali, Mohit Agrawal, Chinnabonia Gopala Krishna, Yogendra Prasad Singh · 2022 · Elsevier eBooks
96. Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans
    Brian Scott Barnett · 2024 · Journal of Psychiatric Practice
97. Efficacy and Tolerability of Two Novel “Standard of Care” Treatments—Intranasal Esketamine Versus Intravenous Ketamine—for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study
    Gilmar Gutiérrez, Joshua Daniel Rosenblat, Emily R. Hawken, Jennifer Swainson, Gustavo Héctor Vázquez · 2022 · JMIR Research Protocols
98. Association of intranasal esketamine, a novel ‘standard of care’ treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice
    Gustavo Héctor Vázquez, Gilmar Gutiérrez, Joshua Daniel Rosenblat, Ayal Schaffer, Jennifer Swainson, Karthikeyan Ganapathy, Nisha Ravindran, Raymond Wing Moon Lam, André Do, Peter Giacobbe et al. · 2022 · BMJ Open
99. A Focus Group Study of Palliative Physician and Consultation-Liaison Psychiatrist Perceptions of Dealing with Depression in the Dying
    Wei Lee, Michelle L DiGiacomo, Brian Draper, Meera Ruth Agar, David C. Currow · 2022 · Journal of Palliative Care
100. Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis
     Li, Jiafeng, Ma, Ling, Sun, Huan, Li, Meng, Cao, Yuan, Peng, Yang, Xu, Jiajun · 2025 · European Archives of Psychiatry and Clinical Neuroscience